Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Texas Children's Heart Center opens Center for Preventive Cardiology

Texas Children's Heart Center is proud to announce the opening of the Center for Preventive Cardiology, which is designed to medically manage the risk factors of acquired heart disease in children. The center is the only one of its kind in Texas that offers multidisciplinary, specialized care for children with these risk factors or who have a strong family history of cardiac disease, elevated cholesterol, high blood pressure or the diagnosis of Kawasaki disease.

13 Dec 2013

Medivir initiates phase IIa trial to evaluate efficacy of simeprevir combination therapy in HCV-infected patients

Medivir AB (STO:MVIR-B) (OMX: MVIR), announces the initiation of a phase IIa trial in chronic genotype 1 hepatitis C infected patients to evaluate the efficacy, safety and tolerability of a 12-week combination therapy of simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor.

12 Dec 2013

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

AstraZeneca and Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy (LD).

12 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Study looks at brain imaging data in veterans who suffered combat-related head injuries

In preliminary findings, Saint Louis University researchers report that veterans who suffered blast injuries have changes in brain tissue that are still apparent in images years after the blast. The data, presented at the annual meeting of the Radiological Society of North America, represents a small but intriguing look at brain imaging in those who suffered combat-related head injuries.

11 Dec 2013

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.

10 Dec 2013

Revised Clinical Practice Guidelines on management of HCV published by EASL

The European Association for the Study of the Liver today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection. The EASL guidelines, which supersede the previous version published in 2011, are designed to help physicians and other healthcare providers optimise their management of patients with acute and chronic HCV.

9 Dec 2013

New project aims to reduce animal testing for drug development

Researchers at the University of East Anglia are launching a new project to develop methods which could one-day decrease the use of rats and mice in pharmaceutical testing.

6 Dec 2013

Researchers update extensive toxicology database to track information about drugs toxic effects

Sometimes the cure can be worse than the disease. Pharmaceutical drugs are known for their potential side effects, and an important aspect of personalized medicine is to tailor therapies to individuals to reduce the chances of adverse events.

6 Dec 2013

Patient survival higher among white children than minorities post liver transplant

Novel research reveals racial and socioeconomic disparities among pediatric liver transplant patients. Findings published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, indicate that graft and patient survival was higher in white children than minorities.

6 Dec 2013

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

MassBiologics of the University of Massachusetts Medical School has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent hepatitis C virus recurrence in patients receiving a liver transplant.

5 Dec 2013

Pro-inflammatory proteins linked to obesity, metabolic syndrome in adults appear to protect young children

The first study of its kind, led by Melinda Sothern, PhD, CEP, Professor and Director of Behavioral and Community Health Sciences at LSU Health Sciences Center New Orleans School of Public Health, reveals that the same pro-inflammatory proteins linked to obesity and the metabolic syndrome in adults appear to protect children prior to puberty.

4 Dec 2013

Virginia Mason first to use non-invasive FibroScan technology to evaluate liver diseases

Virginia Mason today becomes the first in the Pacific Northwest to use non-invasive FibroScan technology to evaluate disease stage in patients diagnosed with liver ailments.

3 Dec 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

Researchers receive $2.5M grant to study telephone-based approach to improve diabetes treatment outcomes

More than 25 million Americans have diabetes, yet as many as 60 percent of type 2 diabetes patients do not follow treatment plans prescribed by their healthcare provider and about 50 percent fail to meet treatment recommendations for control of blood glucose levels.

26 Nov 2013

EMA grants accelerated assessment to Boehringer Ingelheim's Faldaprevir compound

The application for European marketing authorisation of faldaprevir, a potent second generation oral protease inhibitor, has been fully validated and granted accelerated assessment by the European Medicines Agency (EMA).

26 Nov 2013

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

High knowledge about HIV and risky sexual activity does not make teens more likely to get tested for HIV

Having high knowledge about HIV and engaging in risky sexual activity do not make high-school-aged teens more likely to get tested for HIV. Those are the findings of a new study by researchers at Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University.

22 Nov 2013

Extract from bitter melon may have therapeutic qualities to treat head and neck cancer

Extract taken from an Asian vegetable may have therapeutic qualities to treat head and neck cancer, a Saint Louis University researcher has found.

19 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Liver Disease News and Research

Further Reading

Texas Children's Heart Center opens Center for Preventive Cardiology

Medivir initiates phase IIa trial to evaluate efficacy of simeprevir combination therapy in HCV-infected patients

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Study looks at brain imaging data in veterans who suffered combat-related head injuries

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Revised Clinical Practice Guidelines on management of HCV published by EASL

New project aims to reduce animal testing for drug development

Researchers update extensive toxicology database to track information about drugs toxic effects

Patient survival higher among white children than minorities post liver transplant

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

Pro-inflammatory proteins linked to obesity, metabolic syndrome in adults appear to protect young children

Virginia Mason first to use non-invasive FibroScan technology to evaluate liver diseases

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Researchers receive $2.5M grant to study telephone-based approach to improve diabetes treatment outcomes

EMA grants accelerated assessment to Boehringer Ingelheim's Faldaprevir compound

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

High knowledge about HIV and risky sexual activity does not make teens more likely to get tested for HIV

Extract from bitter melon may have therapeutic qualities to treat head and neck cancer

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News